Alzheimer disease
MONDO:0004975A progressive, neurodegenerative disease characterized by loss of function and death of nerve cells in several areas of the brain leading to loss of cognitive function such as memory and language.
Also known as: AD, Alzheimer dementia, Alzheimer disease, Alzheimer's dementia, Alzheimer's disease, Alzheimers disease, presenile and senile dementia, Alzheimer disease, familial
1187 clinical trials for this condition and its sub-types, 1187 tagged with Alzheimer disease itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Part of
Sub-types of Alzheimer disease
-
Familial Alzheimer disease 13 trials · 55 incl. sub-types
2 sub-types
- Early-onset autosomal dominant Alzheimer disease 31 trials · 37 incl. sub-types Sub-types →
- Alzheimer disease 2 11 trials
-
Alzheimer disease 16 1 trial
-
Alzheimer disease 17 1 trial
-
Alzheimer disease 18 1 trial
-
Alzheimer disease 19 1 trial
Most studied deeper sub-types
-
New drug aims to slow Alzheimer's in early stages
Disease control Stopped earlyThis study tests an experimental drug called GSK4527226 in 367 people with early Alzheimer's (mild memory problems or mild dementia). Participants receive either a low dose, high dose, or placebo through an IV. The goal is to see if the drug can slow down declines in memory and d…
Phase 2 • Sponsor: GlaxoSmithKline • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
Can a Melatonin-Like pill slow Alzheimer's memory loss?
Disease control Stopped earlyResearchers are testing whether piromelatine 20 mg, a tablet that acts on melatonin and serotonin receptors, can slow cognitive decline in people aged 60 to 85 with mild dementia from Alzheimer's disease. The study enrolls 216 participants who do not carry a specific genetic vari…
Phase 2/3 • Sponsor: Neurim Pharmaceuticals Ltd. • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
Alzheimer's agitation drug safety trial ends early
Disease control Stopped earlyThis study tested the long-term safety of AXS-05, a combination of dextromethorphan and bupropion, for treating agitation in people with Alzheimer's disease. It enrolled 139 participants who had completed earlier studies. The trial was terminated early, so the full safety picture…
Phase 3 • Sponsor: Axsome Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Alzheimer's drug ALZ-801 tested Long-Term in High-Risk group
Disease control Stopped earlyThis study looked at the long-term safety and effects of ALZ-801, a tablet taken twice daily, in 163 people with early Alzheimer's disease who have the APOE4/4 gene. Participants had already completed a previous phase 3 study. The goal was to see if the drug could slow cognitive …
Phase 3 • Sponsor: Alzheon Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Alzheimer's drug trial halted early – no breakthrough yet
Disease control Stopped earlyThis study tested an experimental drug called SHR-1707 in people with mild memory problems or mild Alzheimer's disease. The goal was to see if it could safely reduce harmful protein clumps in the brain. The trial was stopped early, and it is not expected to cure the disease.
Phase 2 • Sponsor: Shanghai Hengrui Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
Alzheimer's drug TB006 safety study halted early
Disease control Stopped earlyThis study looked at the long-term safety of an experimental drug called TB006 (oloctinebart) in people with Alzheimer's disease. It included 119 participants who had either completed a previous TB006 study or were new to the drug. The study was terminated early, so the full safe…
Phase 2 • Sponsor: TrueBinding, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
Alzheimer's drug trial halted early: what happened?
Disease control Stopped earlyThis early-stage study tested a new drug, ADEL-Y01, in healthy volunteers and people with mild Alzheimer's or mild cognitive impairment. The goal was to check safety and how the drug moves through the body. The trial was stopped early, so results are limited.
Phase 1 • Sponsor: Alzheimer's Disease Expert Lab (ADEL), Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:26 UTC
-
Alzheimer's drug trial halted early after only 8 volunteers
Disease control Stopped earlyThis study tested a drug called PrimeC in people with mild to moderate Alzheimer's disease. The goal was to see if it is safe and if it helps with thinking and daily activities. The study was stopped early and only 8 people took part, so results are very limited.
Phase 2 • Sponsor: NeuroSense Therapeutics Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
Alzheimer's Tau-Targeting antibody trial halted midway
Disease control Stopped earlyThis study tested an experimental antibody called JNJ-63733657 in 523 people with early Alzheimer's disease. The antibody aims to clear tau protein clumps in the brain, which are linked to cognitive decline. Participants received either the antibody or a placebo by IV infusion. T…
Phase 2 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
Brain steroid injection tested for Alzheimer's – but trial halted early
Disease control Stopped earlyThis early study tested a weekly injection of allopregnanolone, a natural brain steroid, in 6 people with early Alzheimer's or mild cognitive impairment. The goal was to find a safe dose and check for side effects. The trial was terminated early, so we have limited information on…
Phase 1 • Sponsor: University of Arizona • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
Alzheimer's drug extension trial halted early — what we know
Disease control Stopped earlyThis study gave Alzheimer's patients who had already completed earlier XPro1595 trials an extra 55 to 74 weeks of the drug to check long-term safety and effects on memory and brain health. Only 11 people took part, and the trial was terminated early, so the findings are limited. …
Phase 2 • Sponsor: Inmune Bio, Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
-
Alzheimer's drug AL002 safety trial ends early
Disease control Stopped earlyThis study was a long-term extension of an earlier trial, testing the safety and tolerability of AL002 in 197 people with early Alzheimer's disease. Participants received the drug by IV infusion. The trial was terminated, meaning it stopped before completion, so the full safety a…
Phase 2 • Sponsor: Alector Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
Early safety trial of ION269 for Alzheimer's in down syndrome ends after just one participant
Disease control Stopped earlyThis early-stage study tested a drug called ION269 in adults with Down syndrome who also showed signs of Alzheimer's disease. The goal was to check if the drug was safe and tolerable when injected into the spinal fluid. Only one person took part, and the study was stopped early, …
Phase 1 • Sponsor: Ionis Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
Alzheimer's drug SPG302 safety study ends early
Disease control Stopped earlyThis study aimed to check the long-term safety and effects of a daily pill called SPG302 in people with mild-to-moderate Alzheimer's disease. It included 12 participants who had already been in a previous SPG302 study. The study was terminated early, so results are limited.
Phase 2 • Sponsor: Spinogenix • Aim: Disease control
Last updated Jun 27, 2026 08:05 UTC
-
Alzheimer's drug trial halted early – what we know
Disease control Stopped earlyThis study tested a drug called varoglutamstat (PQ912) in people with early Alzheimer's disease. The goal was to see if it is safe and if it could slow memory and thinking problems. The trial was stopped early, so we have less information than planned. About 112 people took part,…
Phase 2 • Sponsor: Vivoryon Therapeutics N.V. • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
Alzheimer's drug trial halted early: what happened?
Disease control Stopped earlyThis study tested an experimental drug called REM0046127 in people with mild to moderate Alzheimer's disease. The goal was to see if it was safe and how it affected brain chemicals and brain wave activity. The trial was stopped early and included only 14 participants instead of t…
Phase 2 • Sponsor: reMYND • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC
-
Eczema drug trial halted early: what we know
Disease control Stopped earlyThis study tested an experimental drug called IMG-007 in 13 adults with moderate-to-severe atopic dermatitis (eczema) who did not get enough relief from topical treatments. The main goal was to check the drug's safety, and researchers also looked at how the body processes it and …
Phase 1/2 • Sponsor: Inmagene LLC • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
Alzheimer's agitation drug trial halted early
Disease control Stopped earlyThis study tested a drug called AVP-786 to see if it could safely reduce agitation in people with Alzheimer's dementia over the long term. It was an extension of earlier studies, enrolling over 1,100 participants who had already completed a prior trial. However, the study was ter…
Phase 3 • Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
Alzheimer's drug simufilam trial halted Mid-Study
Disease control Stopped earlyThis study tested a drug called simufilam in over 1,000 people with mild-to-moderate Alzheimer's disease. Participants took either 50 mg, 100 mg, or a placebo twice daily for 76 weeks. The goal was to see if simufilam could slow memory loss and help with daily activities. However…
Phase 3 • Sponsor: Cassava Sciences, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
Eye test may spot Alzheimer's early, study finds
Diagnosis Stopped earlyThis study explored whether a special eye scan (hyperspectral retinal imaging) can detect beta-amyloid, a protein linked to Alzheimer's disease, in the retina. Researchers aimed to see if this non-invasive test could distinguish people with Alzheimer's from healthy individuals. T…
Sponsor: Center for Eye Research Australia • Aim: Diagnosis
Last updated Jun 27, 2026 12:23 UTC
-
Neck-Worn swallow detector fails key test
Diagnosis Stopped earlyThis study tested a wearable device that sits on the neck to detect swallowing problems in people with conditions like stroke, Parkinson's, multiple sclerosis, Alzheimer's, or dementia. The device was compared to a standard X-ray test. Unfortunately, the device did not meet the a…
Sponsor: Société des Produits Nestlé (SPN) • Aim: Diagnosis
Last updated Jun 27, 2026 08:05 UTC
-
Can a headband spot Alzheimer's? new study tests brain wave device
Diagnosis Stopped earlyThis study tested whether a wearable EEG device can help doctors diagnose Alzheimer's disease and mild cognitive impairment. Researchers compared brain wave data from the EEG with standard memory and thinking tests in 148 participants. The goal was to see if the EEG could improve…
Sponsor: Boston University • Aim: Diagnosis
Last updated Jun 27, 2026 08:04 UTC
-
Could a High-Fat diet boost brain health in early Alzheimer's?
Symptom relief Stopped earlyThis study looks at whether a ketogenic diet (high-fat, low-carb) is practical and safe for people with early-stage Alzheimer's disease over one year. The diet may provide an alternative energy source for the brain and reduce inflammation. Researchers will track diet adherence, b…
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Symptom relief
Last updated Sep 12, 2026 00:00 UTC
-
Dementia agitation drug trial halted after just 5 patients
Symptom relief Stopped earlyThis study tested a fast-dissolving film (BXCL501) placed under the tongue to quickly reduce severe agitation in older adults with dementia. The trial aimed to enroll many participants but was stopped early after only 5 people joined. Because it ended so soon, we cannot draw reli…
Phase 2 • Sponsor: BioXcel Therapeutics Inc • Aim: Symptom relief
Last updated Aug 13, 2026 00:00 UTC
-
New Alzheimer's pill shows promise in Mid-Stage trial
Symptom relief Stopped earlyThis study tests whether adding MK-1167 to standard Alzheimer's treatment can improve memory and thinking in people with mild to moderate Alzheimer's dementia. About 350 participants will receive either MK-1167 or a placebo for 24 weeks. Researchers will measure changes in cognit…
Phase 2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Symptom relief
Last updated Jul 03, 2026 00:00 UTC
-
Experimental drug aims to curb disinhibition in dementia patients
Symptom relief Stopped earlyThis study tested a drug called AVP-786 to see if it could safely reduce disinhibition—impulsive or inappropriate behavior—in people with neurodegenerative disorders like Alzheimer's or frontotemporal dementia. The trial planned to include many participants but was terminated ear…
Phase 2 • Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc. • Aim: Symptom relief
Last updated Jun 27, 2026 12:32 UTC
-
Touchscreen device aims to give voice to dementia patients
Symptom relief Stopped earlyThis study tested a personalized touchscreen device (My PATI) to help people with Alzheimer's or related dementias communicate their care preferences. The goal was to improve quality of life for both patients and their caregivers. The study was terminated early, so results are li…
Sponsor: Florida International University • Aim: Symptom relief
Last updated Jun 27, 2026 12:32 UTC
-
New drug aimed at treating apathy in dementia patients tested
Symptom relief Stopped earlyThis study tested a drug called CVL-871 to see if it is safe and can help reduce apathy (lack of motivation or interest) in people with dementia. The trial included 41 participants with mild to moderate dementia and clinically significant apathy. The main goal was to check for si…
Phase 2 • Sponsor: AbbVie • Aim: Symptom relief
Last updated Jun 27, 2026 11:00 UTC
-
Could a Head-Zap at home boost your brain?
Symptom relief Stopped earlyThis study tested whether a gentle, non-invasive brain stimulation technique (tDCS) done at home, along with computer-based brain games, could improve thinking and language skills in people with primary progressive aphasia, mild cognitive impairment, or dementia. Participants use…
Sponsor: Johns Hopkins University • Aim: Symptom relief
Last updated Jun 27, 2026 09:08 UTC
-
Sleep therapy tested for Alzheimer's brain fog
Symptom relief Stopped earlyThis study tested a behavioral program using bright light therapy and sleep coaching to improve sleep and thinking in older adults with mild cognitive impairment or mild Alzheimer's. Only 15 people were enrolled before the study was stopped early. The goal was to see if the progr…
Sponsor: University of California, San Francisco • Aim: Symptom relief
Last updated Jun 27, 2026 07:57 UTC
-
Light helmet for Alzheimer's shows promise, but study cut short
Symptom relief Stopped earlyThis pilot study tested a special helmet and abdominal panel that shines near-infrared light and uses a static magnetic field on people with mild-to-moderate Alzheimer's disease. The goal was to see if it could safely improve memory and thinking. The study planned to enroll 60 pa…
Sponsor: University Hospital, Montpellier • Aim: Symptom relief
Last updated Jun 27, 2026 07:53 UTC
-
App aims to tame chemo side effects in breast cancer
Symptom relief Stopped earlyThis study tested a digital health app called medidux™ in 196 people with HER2-positive breast cancer. The app was used for up to 16 weeks during chemotherapy to help track and manage side effects. The goal was to see if using the app reduced the number of severe side effects. Ho…
Sponsor: Palleos Healthcare GmbH • Aim: Symptom relief
Last updated Jun 27, 2026 07:51 UTC
-
Brain scans reveal why dementia changes personality
Knowledge-focused Stopped earlyThis study investigates how Alzheimer's disease and frontotemporal dementia alter a person's sense of self and ability to understand others. Researchers will compare patients with healthy older adults using questionnaires and brain imaging. The goal is to link changes in self-awa…
Sponsor: University Hospital, Strasbourg, France • Aim: Knowledge-focused
Last updated Jul 15, 2026 00:00 UTC
-
Can pictures help patients understand research better?
Knowledge-focused Stopped earlyThis study tested whether a visual consent form with pictures helps patients with cancer or Alzheimer's understand research better than standard text. Researchers planned to enroll 266 adults across three U.S. sites. The trial was terminated early, so results may be limited.
Sponsor: Washington University School of Medicine • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:01 UTC
-
Tiny brain wave study aims to sharpen Alzheimer's drug testing
Knowledge-focused Stopped earlyThis pilot study measured brain activity (EEG) in 6 healthy volunteers while they performed computer tasks that test attention and memory. The goal was to develop better ways to measure thinking skills that could be used in future Alzheimer's drug trials. The study was terminated…
Sponsor: University Hospital, Lille • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:37 UTC
-
Alzheimer's study probes why patients struggle with daily choices
Knowledge-focused Stopped earlyThis study looked at how early Alzheimer's disease affects a person's ability to make decisions. Researchers tested 100 people with Alzheimer's and healthy volunteers using memory and thinking tasks, plus a special decision-making test. The goal was to understand which brain func…
Sponsor: Centre Hospitalier Universitaire de Saint Etienne • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:31 UTC
-
Alzheimer's drug memantine tested on healthy brains – but study halted early
Knowledge-focused Stopped earlyThis early-stage study aimed to see if taking memantine, an Alzheimer's drug, for 15 days would change certain brain and cognitive markers in healthy young men aged 18-30. The goal was to validate a test battery for future Alzheimer's drug development. However, the study was term…
Phase 1 • Sponsor: University Hospital, Lille • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:29 UTC
-
Zapping the brain to save memories: Alzheimer's study tests new approach
Knowledge-focused Stopped earlyThis study explored whether a non-invasive technique called transcranial magnetic stimulation (TMS) could improve memory in healthy older adults and those with mild memory problems due to Alzheimer's. Researchers used TMS to stimulate brain networks linked to memory and measured …
Sponsor: Massachusetts General Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:03 UTC
-
Robot watchdog: could a roaming robot prevent falls in dementia care?
Knowledge-focused Stopped earlyThis study tested whether a robot that moves on its own could patrol nursing home rooms and detect when a resident with Alzheimer's has fallen. The robot was designed to turn on lights, alert staff, and let them see and talk to the resident through its camera and screen. The stud…
Sponsor: Vigorous Mind, Inc. • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:11 UTC
-
Alzheimer's Anti-Inflammatory trial halted early – what we learned
Knowledge-focused Stopped earlyThis study tested whether anti-inflammatory drugs could help people with early Alzheimer's or mild cognitive impairment. It was stopped early, so only one drug was studied in 34 participants. The main goal was to measure changes in thinking and memory, but the early termination l…
Phase 2 • Sponsor: Novartis Pharmaceuticals • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:54 UTC